Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1)

Naomi A. Fineberg; Eric Hollander; Jon E. Grant; Samuel R. Chamberlain; Lynne M. Drummond; Luca Pellegrini; Keith R. Laws; David Wellsted; Jemma Reid; Vera Nezgovorova; David S. Baldwin

doi:10.1016/j.comppsych.2022.152323

Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1)

Naomi A. Fineberg, Eric Hollander, Jon E. Grant, Samuel R. Chamberlain, Lynne M. Drummond, Luca Pellegrini, Keith R. Laws, David Wellsted, Jemma Reid, Vera Nezgovorova, David S. Baldwin

Psychiatry and Behavioral Sciences

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Article number	152323
Journal	Comprehensive Psychiatry
Volume	116
DOIs	https://doi.org/10.1016/j.comppsych.2022.152323
State	Published - Jul 2022

ASJC Scopus subject areas

Clinical Psychology
Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.comppsych.2022.152323

Cite this

Fineberg, N. A., Hollander, E., Grant, J. E., Chamberlain, S. R., Drummond, L. M., Pellegrini, L., Laws, K. R., Wellsted, D., Reid, J., Nezgovorova, V., & Baldwin, D. S. (2022). Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1). Comprehensive Psychiatry, 116, Article 152323. https://doi.org/10.1016/j.comppsych.2022.152323

Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1). / Fineberg, Naomi A.; Hollander, Eric; Grant, Jon E. et al.
In: Comprehensive Psychiatry, Vol. 116, 152323, 07.2022.

Research output: Contribution to journal › Letter › peer-review

Fineberg, NA, Hollander, E, Grant, JE, Chamberlain, SR, Drummond, LM, Pellegrini, L, Laws, KR, Wellsted, D, Reid, J, Nezgovorova, V & Baldwin, DS 2022, 'Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1)', Comprehensive Psychiatry, vol. 116, 152323. https://doi.org/10.1016/j.comppsych.2022.152323

Fineberg NA, Hollander E, Grant JE, Chamberlain SR, Drummond LM, Pellegrini L et al. Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1). Comprehensive Psychiatry. 2022 Jul;116:152323. doi: 10.1016/j.comppsych.2022.152323

Fineberg, Naomi A. ; Hollander, Eric ; Grant, Jon E. et al. / Commentary on the article : “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1). In: Comprehensive Psychiatry. 2022 ; Vol. 116.

@article{d4c7c9967ea4474296c080df615c41f0,

title = "Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1)",

author = "Fineberg, {Naomi A.} and Eric Hollander and Grant, {Jon E.} and Chamberlain, {Samuel R.} and Drummond, {Lynne M.} and Luca Pellegrini and Laws, {Keith R.} and David Wellsted and Jemma Reid and Vera Nezgovorova and Baldwin, {David S.}",

note = "Funding Information: Prof. Grant has received research grants from Otsuka and Biohaven Pharmaceuticals. He receives yearly compensation from Springer Publishing for acting as Editor-in-Chief of the Journal of Gambling Studies and has received royalties from Oxford University Press, American Psychiatric Publishing, Inc., Norton Press, and McGraw Hill. ",

year = "2022",

month = jul,

doi = "10.1016/j.comppsych.2022.152323",

language = "English (US)",

volume = "116",

journal = "Comprehensive Psychiatry",

issn = "0010-440X",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Commentary on the article

T2 - “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1)

AU - Fineberg, Naomi A.

AU - Hollander, Eric

AU - Grant, Jon E.

AU - Chamberlain, Samuel R.

AU - Drummond, Lynne M.

AU - Pellegrini, Luca

AU - Laws, Keith R.

AU - Wellsted, David

AU - Reid, Jemma

AU - Nezgovorova, Vera

AU - Baldwin, David S.

N1 - Funding Information: Prof. Grant has received research grants from Otsuka and Biohaven Pharmaceuticals. He receives yearly compensation from Springer Publishing for acting as Editor-in-Chief of the Journal of Gambling Studies and has received royalties from Oxford University Press, American Psychiatric Publishing, Inc., Norton Press, and McGraw Hill.

PY - 2022/7

Y1 - 2022/7

UR - http://www.scopus.com/inward/record.url?scp=85129716419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129716419&partnerID=8YFLogxK

U2 - 10.1016/j.comppsych.2022.152323

DO - 10.1016/j.comppsych.2022.152323

M3 - Letter

C2 - 35537294

AN - SCOPUS:85129716419

SN - 0010-440X

VL - 116

JO - Comprehensive Psychiatry

JF - Comprehensive Psychiatry

M1 - 152323

ER -

Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1)

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this